MetaMed Files for IPO: Pioneering Personalized Medicine with AI and Expert-Driven Second Opinions

Previously, VCBeat introduced the 30 most noteworthy undervalued healthcare startups of 2015 (Click here for details.), readers are generally very interested in these companies. VCBeat will continue to monitor the developments of these 30 companies and bring you the latest detailed reports on them. Today marks the first installment of the series “The 30 Most Worth-Watching Healthcare Startups of 2015”: MetaMed, a personalized healthcare services company.According to relevant statistics, approximately 100,000 patients die each year from preventable medical errors. These adverse events frequently occur because patients fail to receive truly timely and appropriate care. The majority of patients are subjected to a “one-size-fits-all” treatment approach.

Based in New York, USA, MetaMed aims to provide patients with more options beyond conventional, one-size-fits-all treatments, helping them find truly personalized treatment plans tailored to their individual needs. In simple terms, MetaMed offers a second medical opinion that is more detailed and thoroughly researched than those provided by most general practitioners.

Why Is Personalized Medicine Necessary?

When people fall ill and require treatment, they generally have two options: the first is, of course, to visit a hospital, and the second is self-diagnosis. For most individuals, self-diagnosis is impractical. This is not only because it is difficult to assess the credibility of online information, with much of the truly useful content requiring payment, but also because locating the specific information needed is challenging. Medicine is exceedingly complex and evolves rapidly; even medical experts cannot guarantee they remain fully abreast of the latest advancements. For instance, the U.S. National Library of Medicine adds 34,000 new medical literature items each month. There are 100,000 prominent medical journals in circulation, and 560,000 new medical papers are published annually. Such an overwhelming volume of information is simply impossible for a general practitioner to fully digest.

For this reason, more than half of patients do not receive treatment truly tailored to their individual conditions; 40 million patients are unable to access timely and effective care due to insufficient information such as medical history and clinical reports. Over the past two decades, misdiagnosis rates have remained largely unchanged.

For many patients, particularly those with critical illnesses, conventional “one-size-fits-all” treatments are not only ineffective but can sometimes even pose life-threatening risks. Therefore, due to individual differences, identical diseases should not always be managed with the same therapeutic approach.

MetaMed’s Dietary Pyramid for a Stroke Patient

Big Data, Artificial Intelligence, and Numerous Experts Craft Personalized Medicine

MetaMed was founded in September 2012 and is headquartered in New York, USA. At its inception, the company secured $500,000 in angel investment from Peter Thiel, a Silicon Valley angel investor. The core leadership team includes CEO Zvi Mowshowitz, Chief Scientist Michael Vassar, and CTO Jaan Tallinn, who is also a co-founder of Skype and Kazaa. Currently, MetaMed employs approximately 40 full-time staff members along with several part-time physicians. Beyond medical professionals, the MetaMed team comprises a diverse range of talents, including computer scientists, applied mathematicians, biologists, and engineers.

When patients seek assistance from MetaMed, experts on the MetaMed team will first assess their current treatment status and therapeutic needs, while comprehensively collecting relevant information such as medical history and physical condition. Based on this information, MetaMed compares the latest scientific research, medical journals, health data, and case studies, leveraging its team of experts and big data analytics to recommend the treatment options with the highest probability of recovery and provide patients with a detailed report. The report includes diagnostic findings, various risk factors that may exacerbate the condition, and multiple detailed treatment alternatives for consideration.

Currently, MetaMed’s starting fee for disease screening and treatment plan analysis services is $5,000. Many users have reported that after undergoing examinations at multiple hospitals, they found the personalized treatment plans provided by MetaMed to be the most effective.

The Future of Personalized Medicine

MetaMed’s services are primarily targeted at high-end clients and patients with severe illnesses, making personalized medicine a relatively niche offering. MetaMed has not obtained FDA approval, and its founder, Michael Vassar, has stated that the company does not intend to seek insurance coverage for its services.

Others have pointed out that those who can afford medical consultants are likely also capable of seeking care at top-tier hospitals for specific conditions, and that physicians generally have sufficient basis for their diagnoses and treatments; therefore, MetaMed’s services lack sufficient appeal.

Nevertheless, many MetaMed users continue to affirm that personalized medical and consulting services offer exceptional value. This is because such services not only provide direct treatment for diseases but also deliver targeted guidance on health maintenance. For instance, a banker based in London stated that, following MetaMed’s diagnosis and proposed treatment plan, he opted for stent placement to manage his heart condition. MetaMed also pointed out that the research underlying other physicians’ diagnoses did not align with his specific circumstances. Compared with traditional hospital diagnostics, he prefers MetaMed’s model and recommends that others engage in personalized healthcare.

To be continued. Next article: “30 Most Promising Healthcare Startups to Watch in 2015” Series – Data Edition 《Flatiron: The Next Oncology Data Company Most Likely to Go Public》。